Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors.
Antoine HollebecqueHyun C ChungMaria J de Miguel LukenAntoine ItalianoJean-Pascal MachielsChia-Chi LinNeesha C DhaniMarc PeetersVictor MorenoWu-Chou SuKay Hoong ChowVioleta R GalvaoMichelle CarlsenDanni YuAnna M SzpurkaYumin ZhaoShelly L SchmidtLeena GandhiXiaojian XuYung-Jue BangPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
LY3300054 monotherapy and combined LY3300054/anti-TIM-3 had manageable safety profiles. Both regimens showed promising clinical activity against PD-1/PD-L1 inhibitor-naïve MSI-H/dMMR tumors. The combination had limited clinical benefit in patients with PD-1/PD-L1 inhibitor-resistant/refractory MSI-H/dMMR tumors.
Keyphrases